Study: Hydroxychloroquine doesn’t improve survival in hospitalized COVID-19 patients, but tocilizumab does – The Cancer Letter

publication date: May. 29, 2020COVID-19 UpdatesAn observational study of more than 3,000 patients hospitalized with COVID-19 at Hackensack Meridian Health has shown that hydroxychloroquine doesn’t improve survival for hospitalized patients. However, tocilizumab appears to improve survival among critically ill intensive care unit patients, the study showed. If confirmed, tocilizumab would become…

Read the full article here

Source: cancerletter.com

Categories: Hem/Onc News and Journals, Latest Headlines

Tags: covid19

Tweets with this article

The Cancer Letter

.@HMHNewJersey study: Hydroxychloroquine doesn’t improve survival in hospitalized #COVID19 patients, but tocilizumab does. https://t.co/UKe7b3hTwb https://t.co/LrfEQ86R0H

Edward M. Copeland III: “My lifestyle was practicing surgery” – The Cancer Letter

In 2013, the American College of Surgeons conducted an oral history interview with former ACS president Edward M. Copeland III. Copeland spoke with archivist Jane…

The Cancer Letter April 18, 2024

Rathmell: To improve funding outlook, we must reverse distrust in science – The Cancer Letter

With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional…

The Cancer Letter April 18, 2024

Edward Copeland, surgeon and breast cancer expert, dies at 86 – The Cancer Letter

A renowned surgeon and international authority on breast cancer, American College of Surgeons Past-President Edward (Ted) M. Copeland III, died on March 31 at the…

The Cancer Letter April 18, 2024

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows – The Cancer Letter

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence…

The Cancer Letter April 18, 2024

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials – The Cancer Letter

An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer…

The Cancer Letter April 18, 2024

OSU—James Immunotherapy Management Clinic to focus on managing immune side effects and cancer control – The Cancer Letter

A clinic at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Pelotonia Immuno-Oncology Institute aims…

The Cancer Letter April 18, 2024

Related Articles